Volume 8, Issue 1

• prodrome conversion to psychosis over time, immunological and neuroimaging putative biomarkers, metabolic syndrome and appropriate �??best practices�?� with antipsychotic medications, compulsory treatment, mental health parity �??comes of age
  Author(s): Peter F. Buckley
  • PDF
• prodrome conversion to psychosis over time, immunological and neuroimaging putative biomarkers, metabolic syndrome and appropriate �??best practices�?� with antipsychotic medications, compulsory treatment, mental health parity �??comes of age
  Author(s): Peter F. Buckley
  • PDF
• Reasons for Adherence and Nonadherence: A Pilot Study Comparing First- and MultiEpisode Schizophrenia Patients
  Author(s): Mamta Sapra, Peter J. Weiden, Nina R. Schooler, Ayako Sunakawa-McMillan, Sarah Uzenoff, Page Burkholder
  • Abstract
  • PDF
• C-Reactive Protein Levels in Schizophrenia: A Review and Meta-Analysis
  Author(s): Brian J. Miller, Nick Culpepper, Mark H. Rapaport
  • Abstract
  • PDF
• Rapid Resolution of Psychotic Symptoms in a Patient with Schizophrenia Using Allopurinol as an Adjuvant: A Case Report
  Author(s): Noah Linden, Angela Onwuanibe, Neil Sandson
  • Abstract
  • PDF
• The Risk of Diabetes in Deficit Schizophrenia
  Author(s): William R. Keller, Carol Vidal 1, 2, Eric S. Park, Gregory P. Strauss, Bernard A. Fischer
  • PDF
• Incidences of Extrapyramidal Symptoms in Patients with Schizophrenia after Treatment with Long-Acting Injection (Depot) or Oral Formulations of Olanzapine
  Author(s): Angela L. Hill, Bin Sun, David P. McDonnell
  • Abstract
  • PDF
• Identification of a Molecular Profile Associated with Immune Status in First-Onset Schizophrenia Patients
  Author(s): Marlis Herberth, Hassan Rahmoune, Emanuel Schwarz, Dagmar Koethe, Laura W. Harris, Laura Kranaster, Stephanie H. Witt, Michael Spain, Anthony Barnes Manfred Schmolz, Markus F. Leweke, Paul C. Guest, Sabine Bahn
  • Abstract
  • PDF